MOTS-C

Description

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) that plays a central role in regulating systemic metabolism and cellular stress responses. Discovered in 2015, MOTS-c challenged the long-held assumption that the mitochondrial genome only encodes structural proteins for the electron transport chain. By revealing that mitochondrial DNA can synthesize signaling peptides, researchers uncovered a direct mechanism by which mitochondria communicate with the cell nucleus. Endogenous plasma levels of MOTS-c naturally decline with age—a reduction that directly correlates with the onset of age-related insulin resistance, metabolic decline, and reduced physical endurance.

At the molecular level, MOTS-c acts primarily by stimulating AMP-activated protein kinase (AMPK), known as the cell’s master energy sensor. Under conditions of metabolic stress or exercise, MOTS-c translocates to the cell nucleus to modulate gene expression, enhancing metabolic flexibility by promoting glucose uptake directly into skeletal muscle independently of insulin pathways. Because its signaling cascade mirrors the cellular adaptations triggered by calorie restriction and vigorous physical exertion, MOTS-c is widely categorized as an exercise mimetic. It optimizes fuel selection between carbohydrates and lipids, helping cells maintain bioenergetic balance even during nutrient stress.

These physiological capabilities have drawn significant attention across clinical, anti-aging, and athletic domains:

• Metabolic & Age-Related Research: Preclinical models demonstrate that MOTS-c administration can reverse high-fat diet-induced obesity, improve skeletal muscle insulin sensitivity, and enhance exercise capacity in aging organisms.

• Anti-Doping & Regulatory Status: Due to its potent performance-enhancing properties and ability to alter metabolic flux, MOTS-c is explicitly banned in professional sports by the World Anti-Doping Agency (WADA) under the category of S4 Metabolic Modulators.

• Therapeutic Limitations: Despite promising preclinical data, MOTS-c remains strictly experimental, lacking standard regulatory approval for human clinical use while research continues into its therapeutic potential for metabolic syndrome and longevity.

For in-vitro research and laboratory use only. Not intended for human or veterinary use. By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.